Herpes zoster infection after rituximab induction therapy in patient with myeloperoxidase-antineutrophil cytoplasmic antibody-associated vasculitis: a case report

Induction treatment with rituximab—an anti-CD20 monoclonal antibody—may increase the risk of varicella-zoster virus (VZV) reactivation in patients with antineutrophil-cytoplasmic-antibody-associated vasculitis (AAV). Our case report shows VZV reactivation following rituximab treatment in AAV patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Chang, Ho-Hsiang, Chen, Hsuan, Lin, Wei-Hung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9759945/
https://www.ncbi.nlm.nih.gov/pubmed/36540838
http://dx.doi.org/10.1093/omcr/omac134
Descripción
Sumario:Induction treatment with rituximab—an anti-CD20 monoclonal antibody—may increase the risk of varicella-zoster virus (VZV) reactivation in patients with antineutrophil-cytoplasmic-antibody-associated vasculitis (AAV). Our case report shows VZV reactivation following rituximab treatment in AAV patients. The recombinant zoster vaccine should be recommended before the start of induction treatment with rituximab.

Ejemplares similares